Roivant Sciences Ltd. (ROIV)
- Previous Close
10.36 - Open
10.30 - Bid 10.44 x 400
- Ask 10.50 x 400
- Day's Range
10.27 - 10.48 - 52 Week Range
8.06 - 13.24 - Volume
4,323,468 - Avg. Volume
7,427,212 - Market Cap (intraday)
8.429B - Beta (5Y Monthly) 1.34
- PE Ratio (TTM)
1.98 - EPS (TTM)
5.27 - Earnings Date Jun 26, 2024 - Jul 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.90
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
roivant.comRecent News: ROIV
Performance Overview: ROIV
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ROIV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ROIV
Valuation Measures
Market Cap
8.36B
Enterprise Value
2.19B
Trailing P/E
1.97
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
67.63
Price/Book (mrq)
1.37
Enterprise Value/Revenue
17.79
Enterprise Value/EBITDA
0.51
Financial Highlights
Profitability and Income Statement
Profit Margin
3,624.14%
Return on Assets (ttm)
-13.77%
Return on Equity (ttm)
105.80%
Revenue (ttm)
123.24M
Net Income Avi to Common (ttm)
4.35B
Diluted EPS (ttm)
5.27
Balance Sheet and Cash Flow
Total Cash (mrq)
6.67B
Total Debt/Equity (mrq)
7.69%
Levered Free Cash Flow (ttm)
-502.47M
Research Analysis: ROIV
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell